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Abstract
Late onset of peritoneal recurrence of gastric cancer more than 10 years after surgery is extremely rare, and only
three cases have been reported. We present the case of a 61-year-old man who was diagnosed finally with perito-
neal recurrence of gastric cancer 20 years after primary curative resection. As a result of small-bowel obstruction
caused by peritoneal recurrence, diverting ileostomy with partial ileal resection was performed. The resected speci-
men revealed tubular adenocarcinoma that resembled the primary gastric cancer. The clinical course after the sec-
ond operation was unfavorable and systemic chemotherapy had no effect. He died at 62 years of age, 21 years
and 7 months after initial gastrectomy. Immunohistochemical analysis using antibodies against proliferating cell
nuclear antigen (PCNA), Ki-67, and p53 was performed to investigate the phenotype of primary and recurrence
cancer. Protein expression of proliferation markers such as PCNA and Ki-67 was down-regulated, but p53 was over-
expressed at the site of recurrence. These data suggest that late peritoneal recurrence has a low proliferation rate
and is resistant to chemoradiotherapy. In conclusion, we present late onset of peritoneal recurrence of gastric can-
cer more than 20 years after primary surgery, and speculate on the mechanism of late-onset recurrence in our
case.
Background
Gastric cancer is a leading cause of tumor-related
deaths, with approximately 50,000 individuals dying of
gastric cancer each year in Japan. Death from gastric
cancer is almost entirely caused by recurrent disease.
Peritoneal recurrence represents one of the most com-
mon causes of failure after curative surgery for gastric
cancer [1-4]. The median survival rate after peritoneal
recurrence is only about 6 months [5]. The prognosis of
peritoneal recurrence is so poor that standard treatment
has not been established. Usually, peritoneal recurrence
occurs within 5 years after surgery, especially during the
first 2 years [5,6], and late-onset peritoneal recurrence
of gastric cancer more than 10 years after surgery is
extremely rare.
We report a case of peritoneal recurrence of gastric
cancer that occurred more than 20 years after curative
surgery, and review previous reports of these cases.
Furthermore, by using immunohistochemical analysis,
we also investigated how expression of several proteins,
such as proliferating cell nuclear antigen (PCNA), Ki67
(cell proliferation), and p53 (resistance to chemora-
diotherapy), differ between primary and secondary
resection samples, and speculate on the mechanism of
late-onset recurrence in our case.
Case report
A 41-year-old man with no remarkable medical history
was referred to our department with a two-month his-
tory of difficulty on swallowing and appetite loss. A bar-
ium study and endoscopic examination showed type 4
advanced gastric cancer in the lesser curvature of the
upper body of the stomach. On admission, the tumor
markers, such as carcinoembryonic antigen(CEA) and
gastrointestinal cancer antigen 19-9 were within normal
limits. He underwent total gastrectomy (D2 dissection)
with splenectomy and distal pancreatectomy for
advanced gastric cancer in the greater curvature of the
corpus. Histological examination of the resected speci-
men revealed tubular adenocarcinoma of the moderately
differentiated type with partial signet-ring cell carci-
noma. The depth of tumor invasion was confirmed as
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(ly1), no venous invasion (v0), and lymph node metasta-
sis (n2). The patient received adjuvant chemotherapy
with oral 5-fluorouracil for 1 year, and was followed up
for 5 years on an outpatient basis without any sign of
recurrence.
At the age of 61 years, 20 years after initial surgery, he
was referred to our hospital with constipation, abdom-
inal distention and lower abdominal pain. Abdominal
computed tomography (CT) showed thickening of the
intestinal wall, moderately accumulated ascites, and left
hydronephrosis. Upper gastrointestinal fiberscope could
demonstrate neither recurrent tumor nor another pri-
mary tumor. Radiographic contrast enema and colono-
scopy could not evaluate the patient adequately because
of extrinsic compression of the sigmoid colon. Tumor
markers such as carcinoembryonic antigen, gastrointest-
inal cancer antigen 19-9, and alpha-fetoprotein were
within normal limits. In contrast, cancer-related antigen
72-4 was elevated slightly. Laparotomy was performed
because small-bowel obstruction could not be relieved
by conservative therapy. At laparotomy, multiple white
nodules (~10 mm) were observed within the mesentery
proper (Figure 1a and 1b). Stenosis caused by these
nodules was recognized in the descending and sigmoid
colon. In addition, we checked other organs which con-
tain remnant pancreas head, small intestine, colon and
other intra-abdominal organs, and operative findings
could not demonstrated primary other cancer. We diag-
nosed peritoneal dissemination from an unknown pri-
mary lesion, and diverting ileostomy with partial ileal
resection was performed.
Histological examinationf o rt h e s ew h i t en o d u l e s
revealed tubular adenocarcinoma with signet-ring cell
carcinoma, which was similar to the pathological find-
ings of the gastric tumor 20 years earlier (Figure 1c and
1d). Immunohistochemical staining using antibody to
pancytokeratin (pan-CK; 1:50; NovoCastro, Newcastle,
UK) showed that cancer cells were expressed in recur-
rent specimens (Figure 2a). The immunohistochemical
staining for cytokeratin-7 (CK-7; 1:50; DAKO, Glostrup,
Denmark) was not expressed both in primary and disse-
minated cancer cells (Figure 2b and 2c). In addition,
immnohistochemical staining for CK-20 (1:25; DAKO,
Glostrup, Denmark) was also not expressed both in pri-
mary and disseminated 6cancer cells (Figure 2d and 2e).
The intensity of staining for Ki-67 (1:50; Zymed, San
Francisco, CA, USA) and PCNA (1:100; DAKO,
Glostrup, Denmark) was decreased in recurrent cancer
cells in comparison to primary cancer specimens (Figure
2f-i). On the other hand, staining for p53 (1:100;
DAKO) was more positive and diffuse in recurrent than
primary cancer cells (Figure 2j and 2k).
Systemic reevaluation, including total colonoscopy and
systemic computed tomography, could not confirm
another primary tumor as the cause of the recurrence,
therefore, peritoneal recurrence of gastric cancer more
than 20 years after primary surgery was diagnosed. Fol-
low-up systemic computed tomography at 1 year after
the second operation could not showed primary other
lesion responsible for peritoneal dissemination. The
patient’s general condition after secondary surgery took
a gradual turn for the worse, despite 5-fluorouracil-
based systemic chemotherapy, and he died at 62 years
of age, 21 years and 7 months after initial gastrectomy.
Discussion
Although sites of recurrence of gastric cancer include
the peritoneum, liver, bone marrow and lymph nodes,
Figure 1 At laparotomy, multiple white nodules (~10 mm)
were observed within the mesentery proper (a). Resected
specimens showed a whitish, hard nodule (12 × 10 mm) at the site
of mesenteric attachment (b). Hematoxylin and eosin staining of
primary cancer (c, × 100) and site of recurrence (d, × 100).
Figure 2 Immunohistochemical staining of primary cancer and
recurrent focus. pan-CK at site of recurrence (a, × 100); CK-7 in
primary (b, × 200) and recurrent (c, × 200) cancer; CK-20 in primary
(d, × 200) and recurrent (e, × 200) cancer; Ki-67 in primary (f, × 200)
and recurrent (g, × 200) cancer; PCNA in primary (h, × 200) and
recurrent (i, × 200) cancer; and p53 in primary (j, × 100) and
recurrent (k, × 100) cancer.
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recurrence [7,8]. Peritoneal recurrence in gastric cancer
has been reported in 17% of patients who underwent
curative resection [5]. Especially in advanced gastric can-
cer, peritoneal recurrence is more frequent. Peritoneal
recurrence of gastric cancer is thought to occur by
spreading through the serosa or the lymphatic or vascu-
lar systems [4,9]. Then, peritoneal recurrence is involved
closely with advanced invasion of the serosa and lymph
node metastasis.
Shiraishi et al have compared early and late recurrence
after gastrectomy for gastric cancer patients, and have
reported that tumor size, lymphatic invasion, level of
lymph node metastasis, stage of disease, and extent of
lymph node dissection are the factors associated most
significantly with early recurrence within 2 years after
gastrectomy [10]. In contrast, Moon et al [11] have
recently reported the changing pattern of prognostic
indicators during 15 years’ follow-up of advanced gastric
cancer after gastrectomy and adjuvant chemotherapy.
They have suggested that tumor factors, including stage,
were clinical prognostic indicators within 5 years post-
gastrectomy, but there were no such indicators after
10 years.
Previously, there have been only three reported cases
in which peritoneal recurrence occurred more than 10
years after primary resection (Table. 1). Aihara et al
[12] have demonstrated peritoneal recurrence of pri-
mary advanced gastric cancer, with serosal invasion (se)
accompanied with lymph node metastasis (n2), 12 years
after curative resection. Moon et al [11] have reported
two cases of peritoneal recurrence with or without dis-
tant metastasis at 12-14 years after radical gastrectomy.
In our case, late-onset peritoneal recurrence was
detected more than 20 years after curative gastrectomy,
regardless of the primary advanced stage with serosal
invasion and lymph node metastasis. All reviewed cases,
including the present one, support the possibility that
late-onset peritoneal recurrence of gastric cancer after
more than 10 years has no prognostic indicators. This
is because these cases of peritoneal recurrence were
from advanced gastric cancer, and the mechanism of
such late-onset recurrence of gastric cancer remains
unclear.
We also assessed both the organ specificity of dissemi-
nated lesion and the mechanism of late-onset recurrence
of gastric cancer by immunohistochemistry using pan-
CK, CK-7, and CK-20 as a indicator of epithelial differ-
entiation [13-16], p53 as a chemo-radioresistance
marker [17], PCNA, and Ki-67 as a cell proliferation
marker [18,19]. CK-7 and CK-20 have been used for
immunophenotyping of metastases and primary adeno-
carcinomas a the study by Wauters et al [14]. In our
case, primary gastric cancer showed the same CK-7/CK-
20 expression pattern as disseminated lesion. The CK-
7
-/CK-20
- pattern was reported to be found from 10%
to 25% of gastric carcinoma [15,16], and these data
might support the diagnosis of the peritoneal dissemina-
tion of gastric cancer 20 years after curative resection.
Furthermore, recurrent cancer cells expressed Ki-67 and
PCNA at a lower level than the primary lesion in each
specimen. On the other hand, staining with antibodies
against p53 revealed that recurrent cancer cells had
higher expression of mutant p53 than primary cancer
cells did. The clinical course corroborated these find-
ings, which suggest that recurrent cancer cells have slow
proliferation and are resistant to chemotherapy.
Conclusions
In conclusion, we report an extremely rare case of peri-
toneal recurrence detected 20 years after curative sur-
gery for advanced gastric cancer. Regardless of the
advanced stage, peritoneal recurrence should be consid-
ered as one of the recurrence patterns of gastric cancer
during long follow-up in patients for more than
10 years after curative gastrectomy.
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